The Arc is the nation’s largest and leading organization for people with intellectual and developmental disabilities (I/DD) and their families with a 60 year history of promoting and protecting the rights of people with I/DD and providing them the opportunity to live full, satisfying and self-determined lives as valued and contributing members of their communities.

Si tiene un niño o miembro de la familia con discapacidad, por favor llame 615-248-5878 ext. 17 para más información.

Donate to The Arc of Tennessee today without opening your wallet… how? IT’S EASY! Sign up to take online surveys through Opinions for Good (OP4G) and choose The Arc of Tennessee as your non-profit of choice!  Sign up now by clicking HERE.

The Arc TN is assisting Vanderbilt Kennedy Center TRIAD in gathering information from individuals with ASD (Autism Spectrum Disorder) and their families regarding how they access and identify activities/events for their family to participate in. If you would like to complete the survey, click HERE.

The Arc Tennessee and the Vanderbilt Kennedy Center are seeking one hour interviews with individuals with disabilities and/or families who live in rural areas of Tennessee for inclusion in Kindred Stories of Disability: Rural Issues. Stories collected will be shared with legislators and policymakers. Questions will be shared with participants in advance and will focus on a variety of potential barriers to disability services. If you are willing to participate in an interview over the phone during the month of October, please send an email (with “Kindred Stories” in the subject line) to:  courtney.taylor@vanderbilt.edu.

Opportunity to Participate in Autism Clinical Trial
Vanderbilt University Medical Center is looking for children and adolescents, ages 5-17, for a study involving a new medication for Autism. The aViation study will test a potential new treatment for ‘high-functioning’ autism spectrum disorder (ASD). The investigational study drug blocks a hormone receptor in the brain that is linked to the control of socialization, stress, anxiety and aggression. Participation lasts for up to 39 weeks. For 24 of those weeks, they will take daily doses of either the investigational study drug or a placebo (a look-alike) that contains no medicine. Both the investigational study drug and the placebo are small tablets that can be swallowed whole or dissolved in liquid. Your time will be compensated. This study is sponsored by Roche Pharmaceuticals. Enrollment will continue until the end of 2017. If interested, please contact Matthew Maloney at 615-343-2018 or matthew.maloney@vanderbilt.edu.

logo AutismNow

Like us on


Alternative formats available upon request. Email info@thearctn.org.

This project is partially funded under an agreement with the State of Tennessee.

stop spam